These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 10832595)

  • 21. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
    Kahán Z; Nagy A; Schally AV; Hebert F; Sun B; Groot K; Halmos G
    Int J Cancer; 1999 Aug; 82(4):592-8. PubMed ID: 10404076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
    Szepeshazi K; Schally AV; Keller G; Block NL; Benten D; Halmos G; Szalontay L; Vidaurre I; Jaszberenyi M; Rick FG
    Oncotarget; 2012 Jul; 3(7):686-99. PubMed ID: 22824624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.
    Szepeshazi K; Schally AV; Block NL; Halmos G; Nadji M; Szalontay L; Vidaurre I; Abi-Chaker A; Rick FG
    Oncotarget; 2013 May; 4(5):751-60. PubMed ID: 23744510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
    Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
    Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone.
    Danila DC; Schally AV; Nagy A; Alexander JM
    Proc Natl Acad Sci U S A; 1999 Jan; 96(2):669-73. PubMed ID: 9892691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
    Arencibia JM; Schally AV; Krupa M; Bajo AM; Nagy A; Szepeshazi K; Plonowski A
    Int J Oncol; 2001 Sep; 19(3):571-7. PubMed ID: 11494038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
    Szepeshazi K; Schally AV; Halmos G; Szoke B; Groot K; Nagy A
    Breast Cancer Res Treat; 1996; 40(2):129-39. PubMed ID: 8879679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
    Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
    Arencibia JM; Schally AV; Halmos G; Nagy A; Kiaris H
    Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
    Halmos G; Schally AV; Kahan Z
    Int J Oncol; 2000 Aug; 17(2):367-73. PubMed ID: 10891548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G; Sindermann H; Engel J; Schally AV; Gründker C
    Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
    Lamharzi N; Halmos G; Jungwirth A; Schally AV
    Int J Oncol; 1998 Sep; 13(3):429-35. PubMed ID: 9683774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
    Milovanovic SR; Monje E; Szepeshazi K; Radulovic S; Schally A
    J Cancer Res Clin Oncol; 1993; 119(5):273-8. PubMed ID: 8382705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
    Szepeshazi K; Schally AV; Nagy A
    Breast Cancer Res Treat; 1999 Aug; 56(3):267-76. PubMed ID: 10573117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
    Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
    Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
    Kahán Z; Varga JL; Schally AV; Rékási Z; Armatis P; Chatzistamou L; Czömpöly T; Halmos G
    Breast Cancer Res Treat; 2000 Mar; 60(1):71-9. PubMed ID: 10845811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.